TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation (original) (raw)

• Short Communication
• Published: 09 June 2008
• A Dobi1,6 na1,
• A Mohamed1,
• H Li1,
• R L Thangapazham1,
• B Furusato1,2,
• S Shaheduzzaman1,
• S-H Tan1,
• G Vaidyanathan1,
• E Whitman1,3,
• D J Hawksworth1,3,
• Y Chen1,
• M Nau4,
• V Patel5,
• M Vahey4,
• J S Gutkind5,
• T Sreenath1,
• G Petrovics1,
• I A Sesterhenn2,6,
• D G McLeod1,3,6 &
• …
• S Srivastava1,6

Oncogene volume 27, pages 5348–5353 (2008)Cite this article

• 3823 Accesses
• 188 Citations
• 6 Altmetric
• Metrics details

Abstract

The high prevalence of TMPRSS2-ERG rearrangements (∼60%) in prostate cancer (CaP) leads to androgenic induction of the _ETS_-related gene (ERG) expression. However, the biological functions of ERG overexpression in CaP remain to be understood. ERG knockdown in TMPRSS2-ERG expressing CaP cells induced striking morphological changes and inhibited cell growth both in cell culture and SCID mice. Evaluation of the transcriptome and specific gene promoters in ERG siRNA-treated cells and investigation of gene expression signatures of human prostate tumors revealed ERG-mediated activation of C-MYC oncogene and the repression of prostate epithelial differentiation genes (PSA and _SLC45A3/_Prostein). Taken together, these data combining cell culture and animal models and human prostate tumors reveal that ERG overexpression in prostate tumor cells may contribute to the neoplastic process by activating C-MYC and by abrogating prostate epithelial differentiation as indicated by prostate epithelial specific markers.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 50 print issues and online access

$259.00 per year

only $5.18 per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

• Log in
• Learn about institutional subscriptions
• Read our FAQs
• Contact customer support

Similar content being viewed by others

References

• Baldus CD, Burmeister T, Martus P, Schwartz S, Gokbuget N, Bloomfield CD et al. (2006). High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24: 4714–4720.
  Article CAS Google Scholar
• De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256–269.
  Article CAS Google Scholar
• Demichelis F, Rubin MA . (2007). TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol 60: 1185–1186.
  Article Google Scholar
• Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG et al. (2008). Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 21: 67–75.
  Article CAS Google Scholar
• Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI et al. (2006). TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66: 10242–10246.
  Article CAS Google Scholar
• Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD et al. (2008). A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105: 2105–2110.
  Article Google Scholar
• Korenchuk S, Lehr JE, Mclean L, Lee YG, Whitney S, Vessella R et al. (2001). VCaP, a cell-based model system of human prostate cancer. In Vivo 15: 163–168.
  CAS Google Scholar
• Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD et al. (1999). Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 59: 4180–4184.
  CAS Google Scholar
• Marcucci G, Mrozek K, Bloomfield CD . (2005). Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 12: 68–75.
  Article CAS Google Scholar
• Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE et al. (2007). New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8: 871–878.
  Article CAS Google Scholar
• Meulia T, Krumm A, Spencer C, Groudine M . (1992). Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter. Mol Cell Biol 12: 4590–4600.
  Article CAS Google Scholar
• Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J et al. (2000). PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 275: 1216–1225.
  Article CAS Google Scholar
• Owczarek CM, Portbury KJ, Hardy MP, O'Leary DA, Kudoh J, Shibuya K et al. (2004). Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene 324: 65–77.
  Article CAS Google Scholar
• Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y et al. (2005). Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24: 3847–3852.
  Article CAS Google Scholar
• Scherf M, Epple A, Werner T . (2005). The next generation of literature analysis: integration of genomic analysis into text mining. Brief Bioinform 6: 287–297.
  Article CAS Google Scholar
• Seth A, Watson DK . (2005). ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462–2478.
  Article CAS Google Scholar
• Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Banez L et al. (2007). Silencing of lactotransferrin expression by methylation in prostate cancer progression. Cancer Biol Ther 6: 1–8.
  Article Google Scholar
• Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595–599.
  Article CAS Google Scholar
• Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE et al. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177–188.
  Article CAS Google Scholar
• Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648.
  Article CAS Google Scholar
• Turner DP, Watson DK . (2008). ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther 8: 33–42.
  Article CAS Google Scholar
• Witte JS . (2007). Multiple prostate cancer risk variants on 8q24. Nat Genet 39: 579–580.
  Article CAS Google Scholar

Download references

Acknowledgements

Authors express sincere thanks to Ms Lakshmi Ravindranath, Ms Atekelt Y Tadese, Ms Suma Ravulapalli and Mr Christopher Cook for their superb technical support of this study. The prostate tissue specimens used in this study were obtained under an IRB-approved protocol at Walter Reed Army Medical Center. This work was funded by the CPDR through an ongoing grant from the US Army Medical Research and Materiel Command, NIH Grants RO1 DK065977 to S.S and G.P. and RO1 CA106653 to S.S. and A.D. The views expressed in this manuscript are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense or the US Government.

Author information

Author notes

1. C Sun and A Dobi: These authors contributed equally to this work.

Authors and Affiliations

1. Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Rockville, MD, USA
   C Sun, A Dobi, A Mohamed, H Li, R L Thangapazham, B Furusato, S Shaheduzzaman, S-H Tan, G Vaidyanathan, E Whitman, D J Hawksworth, Y Chen, T Sreenath, G Petrovics, D G McLeod & S Srivastava
2. Department of Genitourinary Pathology, Armed Forces Institute of Pathology, Washington, DC, USA
   B Furusato & I A Sesterhenn
3. Department of Surgery, Urology Service, Walter Reed Army Medical Center, Washington, DC, USA
   E Whitman, D J Hawksworth & D G McLeod
4. Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD, USA
   M Nau & M Vahey
5. Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
   V Patel & J S Gutkind
6. US Military Cancer Institute, Washington, DC, USA
   A Dobi, I A Sesterhenn, D G McLeod & S Srivastava

Authors

1. C Sun
   You can also search for this author inPubMed Google Scholar
2. A Dobi
   You can also search for this author inPubMed Google Scholar
3. A Mohamed
   You can also search for this author inPubMed Google Scholar
4. H Li
   You can also search for this author inPubMed Google Scholar
5. R L Thangapazham
   You can also search for this author inPubMed Google Scholar
6. B Furusato
   You can also search for this author inPubMed Google Scholar
7. S Shaheduzzaman
   You can also search for this author inPubMed Google Scholar
8. S-H Tan
   You can also search for this author inPubMed Google Scholar
9. G Vaidyanathan
   You can also search for this author inPubMed Google Scholar
10. E Whitman
    You can also search for this author inPubMed Google Scholar
11. D J Hawksworth
    You can also search for this author inPubMed Google Scholar
12. Y Chen
    You can also search for this author inPubMed Google Scholar
13. M Nau
    You can also search for this author inPubMed Google Scholar
14. V Patel
    You can also search for this author inPubMed Google Scholar
15. M Vahey
    You can also search for this author inPubMed Google Scholar
16. J S Gutkind
    You can also search for this author inPubMed Google Scholar
17. T Sreenath
    You can also search for this author inPubMed Google Scholar
18. G Petrovics
    You can also search for this author inPubMed Google Scholar
19. I A Sesterhenn
    You can also search for this author inPubMed Google Scholar
20. D G McLeod
    You can also search for this author inPubMed Google Scholar
21. S Srivastava
    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence toA Dobi or S Srivastava.

Additional information

Supplementary information

Rights and permissions

About this article

Cite this article

Sun, C., Dobi, A., Mohamed, A. et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.Oncogene 27, 5348–5353 (2008). https://doi.org/10.1038/onc.2008.183

Download citation

• Received: 26 February 2008
• Revised: 08 April 2008
• Accepted: 01 May 2008
• Published: 09 June 2008
• Issue Date: 11 September 2008
• DOI: https://doi.org/10.1038/onc.2008.183

Keywords

This article is cited by